Navigation Links
Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Date:2/4/2008

MONTREUX, Switzerland, Feb. 4 /PRNewswire/ -- Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.

The study was presented yesterday at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders in Montreux, Switzerland.(1) This one-year, phase 3, trial is the first placebo-controlled study to explore the use of a long-acting injection medication in the maintenance treatment of frequently relapsing bipolar disorder (FRBD). FRBD, defined as four or more manic or depressive episodes in the previous year that require a doctor's care, may affect 20% of the 27 million people with bipolar disorder worldwide(2,3).

The study compared the time to the next mood episode, also known as a relapse, in FRBD patients receiving RLAI plus standard treatment vs. patients receiving placebo plus standard treatment. For most patients, standard treatment consisted of mood stabilizers, antidepressants, anxiolytics or combinations thereof. The trial showed that time to relapse was significantly longer in patients receiving RLAI compared with placebo (p=0.004) and the relative risk of relapse was 2.4 times higher with placebo. The relapse rates were 47.8% with placebo and 22.2% with RLAI.

"Patients with frequently relapsing bipolar disorder require more healthcare interventions than patients with fewer episodes, and there is a huge unmet need for new treatments," said Dr. Joseph Calabrese, Co-Director of the Bipolar Disorders Research Center, University Hospitals Case Medical Center, Case Western Reserve University. Dr. Calabrese is a consultant to the study sponsors, Ortho-McNeil Janssen Scientific Affairs, L.L.C. "Risperidone long-acting injection is adm
'/>"/>

SOURCE Janssen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
10. Study Examines Media Preferences of Life Scientists in Applied Markets
11. Triage study challenges notions of emergency medical response to disaster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... ON , April 23, 2015 /CNW/ - A ... sustainable packaging award from North America,s ... Brandcheck Competitor Comparison won Silver in the "Sustainability, ... The Brandcheck "Competitor Comparison" is a ... of North American and Global peers. This benchmarking ...
(Date:4/23/2015)... D.C. (PRWEB) April 23, 2015 ... D.C. region on April 4-17 as part of ... marks the fourth group of biotechnology startups to ... of Nizhny Novgorod (UNN) and the University of ... deepen ties between their respective universities in the ...
(Date:4/23/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology and medical device industries, with ... the United States , today announced that ... of 2015 after the New York Stock Exchange closes ... morning, May 14, 2015 Shanghai time). The earnings release ...
(Date:4/23/2015)... LAKE FOREST, Calif. , April 23, 2015 ... provider of advanced cryogenic logistics solutions for the ... has further established its cryogenic logistics solutions within ... customer agreement with Yancey Farms to support the ... top German Sport horse Stallions. ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3
... Ltd,(SWX: ARPN) announced today the results of a ... iclaprim and warfarin.,Warfarin is widely used for the ... to be well-controlled.The drug-drug interaction study,comprised 24 healthy ... with and without pre- and co-administration of iclaprim ...
... Acclaimed stem cell researcher Shinya Yamanaka, MD, PhD, ... have successfully reprogrammed human adult cells to function like ... much of the controversy and restrictions regarding generation of ... in the journal Cell, should accelerate the pace of ...
... - Appointment of Company Officers ... ... - 1 Stock ... Meeting held on,November 7 2007, Monica R. Brettler, Tush P. Nikollaj, Carl H. Rosner and,Arthur Roth were elected to ...
Cached Biology Technology:Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim 2Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim 3Shinya Yamanaka reprograms human adult cells 2CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting 2
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... do undergraduate students gain valuable hands-on experience by participating ... contributions, examples of which are highlighted in the current ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... This special issue features a collection of papers ...
... Scientists at The Scripps Research Institute have designed a new ... drugs targeting a human metabolic enzyme believed to stimulate the ... new test, which the scientists call a simple assay, will ... for those that have potential to block the action of ...
... LA JOLLA, CA September 16, 2010 For Immediate ... been awarded a four-year, $5.1 million grant as part of ... development of the next generation of DNA sequencing technologies, which ... sequence a person,s DNA. With the new grant, ...
Cached Biology News:Undergraduate research highlighted in DNA and Cell Biology Journal 2Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 2Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 3Scripps research team wins $5.1 million to develop DNA sequencing technology 2
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
... The CERTOMAT IS, a true benchtop incubator-shaker, has ... Having a footprint of 540 x 680 ... large incubation chamber (370 x 505 x 510mm). ... the CERTOMAT IS is ideal for shaking applications ...
... TC-3000 is one of the smallest thermal cyclers ... choice of either the 0.5ml (20 samples) or ... , Fast heating and cooling rate of ... and high performance Fast track programming with ...
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Biology Products: